SkinBioTherapeutics is a promising life science company that strives to enhance skin health through its unique platform technology, SkinBiotix®. This proprietary technology is the result of extensive research conducted by the CEO, Dr. Catherine O’Neill, and Professor Andrew McBain at The University of Manchester. By applying lysates derived from probiotic bacteria to the skin, SkinBioTherapeutics' platform has shown to improve the barrier effect of skin models, promote repair and reduce bacterial load. This innovative technology has great potential in the skin health industry.